YaoKang Biotech announced that China National Pharmaceutical Group plans to reduce its shareholding in the company through bulk trading, with the number of shares not exceeding 6.15 million, accounting for 1.50% of the total share capital.
药康生物：青岛国药拟减持不超过1.50%股份
Yao Kang Biology: Qingdao National Medicine intends to reduce its shareholding by no more than 1.50%.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.